NovoCure (NVCR) Projected to Announce Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to be posting its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $172.7180 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:00 AM ET.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). NovoCure had a negative net margin of 25.66% and a negative return on equity of 50.82%. The business had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same quarter last year, the business earned ($0.31) EPS. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts expect NovoCure to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NovoCure Trading Up 0.4%

NVCR opened at $16.00 on Wednesday. NovoCure has a fifty-two week low of $9.82 and a fifty-two week high of $18.92. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.90 and a quick ratio of 2.70. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -10.46 and a beta of 0.94. The company’s 50 day moving average price is $16.65 and its two-hundred day moving average price is $14.05.

Analyst Ratings Changes

NVCR has been the subject of several analyst reports. Evercore reaffirmed an “outperform” rating on shares of NovoCure in a research note on Friday, May 1st. Weiss Ratings raised shares of NovoCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Zacks Research downgraded NovoCure from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Wells Fargo & Company raised their target price on NovoCure from $13.50 to $17.00 and gave the stock an “equal weight” rating in a research report on Monday, May 4th. Finally, Wedbush reaffirmed a “neutral” rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, April 16th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $23.60.

Insider Buying and Selling at NovoCure

In other NovoCure news, Director Timothy J. Scannell sold 2,945 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the transaction, the director owned 14,288 shares in the company, valued at approximately $225,321.76. This trade represents a 17.09% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeryl L. Hilleman sold 2,945 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $15.77, for a total transaction of $46,442.65. Following the completion of the sale, the director directly owned 13,861 shares in the company, valued at approximately $218,587.97. This represents a 17.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 51,943 shares of company stock worth $893,171. Company insiders own 5.52% of the company’s stock.

Institutional Investors Weigh In On NovoCure

Several institutional investors and hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC increased its holdings in NovoCure by 178.0% in the fourth quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock worth $1,259,000 after purchasing an additional 62,341 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its position in shares of NovoCure by 14.5% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock worth $422,000 after buying an additional 4,124 shares during the period. Empowered Funds LLC acquired a new stake in shares of NovoCure during the 4th quarter worth approximately $33,000. XTX Topco Ltd increased its stake in shares of NovoCure by 159.2% in the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock valued at $760,000 after acquiring an additional 36,111 shares in the last quarter. Finally, Vestal Point Capital LP increased its stake in shares of NovoCure by 31.2% in the 4th quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock valued at $6,788,000 after acquiring an additional 125,000 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.